Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now
12:30pm, Tuesday, 04'th Oct 2022 Zacks Investment Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average
11:17am, Tuesday, 04'th Oct 2022
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?
10:32am, Tuesday, 04'th Oct 2022
Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.
13 Analysts Have This to Say About Regeneron Pharmaceuticals
09:04pm, Monday, 03'rd Oct 2022 Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
5
6
0
What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
07:38pm, Monday, 03'rd Oct 2022 Benzinga
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
5
6
Market Indexes Jump Higher As Oil Leads; Denbury, Sinclair, Regeneron In Focus | Stock Market Today
03:51pm, Monday, 03'rd Oct 2022
Big gains for market indexes doesn't mean the correction is over. Stock Market Today: October 3, 2022 Hosts: Ali Coram & Ed Carson Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Vi
Analyst Ratings for Regeneron Pharmaceuticals
02:18pm, Monday, 03'rd Oct 2022 Benzinga
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
5
6
9 Stocks Turned $10,000 Into $129,224 In 9 Months
08:00am, Friday, 30'th Sep 2022
It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
04:12pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
03:09pm, Thursday, 29'th Sep 2022 Zacks Investment Research
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
Ocular (OCUL) Announces Positive Data on Wet AMD Candidate
03:19pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acu
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
10:20am, Monday, 26'th Sep 2022 Zacks Investment Research
Style Box ETF report for GSEW
Piper Sandler's Kantrowitz likes stocks with Regeneron and General Mills
04:32pm, Friday, 23'rd Sep 2022
Michael Kantrowitz, Piper Sandler chief investment strategist, joins 'Power Lunch' to discuss the companies he thinks investors should buy, the names to avoid and what will happen to companies with po
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
03:30pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
04:28pm, Monday, 19'th Sep 2022 Zacks Investment Research
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.
